Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Novel agents for anti-platelet therapy. | Ji and Hou Journal of Hematology Oncology 2011 4 44 http www.jhoonline.Org content 4 1 44 JOURNAL OF HEMATOLOGY ONCOLOGY REVIEW Open Access Novel agents for anti-platelet therapy Xuebin Ji and Ming Hou Abstract Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs namely aspirin ticlopidine and clopidogrel are effective in the prevention and treatment of cardio-cerebrovascular diseases. Glycoprotein IIb IIIa antagonists e.g. abciximab eptifibatide and tirofiban have demonstrated good clinical benefits and safety profiles in decreasing ischemic events in acute coronary syndrome. However adverse events related to thrombosis or bleeding have been reported in cases of therapy with glycoprotein IIb IIIa antagonists. Cilostazol is an anti-platelet agent used in the treatment of patients with peripheral ischemia such as intermittent claudication. Presently platelet adenosine diphosphate P2Y 12 receptor antagonists e.g. clopidogrel prasugrel cangrelor and ticagrelor are being used in clinical settings for their pronounced protective effects. The new protease-activated receptor antagonists vorapaxar and atopaxar potentially decrease the risk of ischemic events without significantly increasing the rate of bleeding. Some other new anti-platelet drugs undergoing clinical trials have also been introduced. Indeed the number of new antiplatelet drugs is increasing. Consequently the efficacy of these anti-platelet agents in actual patients warrants scrutiny especially in terms of the hemorrhagic risks. Hopefully new selective platelet inhibitors with high antithrombotic efficiencies and low hemorrhagic side effects can be developed. Keywords anti-platelet agent therapy antagonist thrombotic disease Introduction Thrombotic diseases and their complications may have severe consequences. Platelets play a key role in thrombosis and anti-platelet therapies may prevent as well as treat thrombotic .
